RS68167B1 - Bioerodibilni okularni uložak za isporuku leka i terapeutski postupak - Google Patents
Bioerodibilni okularni uložak za isporuku leka i terapeutski postupakInfo
- Publication number
- RS68167B1 RS68167B1 RS20260673A RSP20260673A RS68167B1 RS 68167 B1 RS68167 B1 RS 68167B1 RS 20260673 A RS20260673 A RS 20260673A RS P20260673 A RSP20260673 A RS P20260673A RS 68167 B1 RS68167 B1 RS 68167B1
- Authority
- RS
- Serbia
- Prior art keywords
- cartridge
- pva
- day
- days
- hydrolyzed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts or implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0076—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof multilayered, e.g. laminated structures
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078265P | 2020-09-14 | 2020-09-14 | |
| US202163176430P | 2021-04-19 | 2021-04-19 | |
| US202163190052P | 2021-05-18 | 2021-05-18 | |
| EP21867765.6A EP4210682B1 (en) | 2020-09-14 | 2021-09-13 | Bioerodible ocular drug delivery insert and therapeutic method |
| PCT/US2021/050085 WO2022056392A1 (en) | 2020-09-14 | 2021-09-13 | Bioerodible ocular drug delivery insert and therapeutic method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS68167B1 true RS68167B1 (sr) | 2026-06-30 |
Family
ID=80629914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20260673A RS68167B1 (sr) | 2020-09-14 | 2021-09-13 | Bioerodibilni okularni uložak za isporuku leka i terapeutski postupak |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US12551368B2 (enExample) |
| EP (2) | EP4696325A3 (enExample) |
| JP (1) | JP7848190B2 (enExample) |
| KR (1) | KR20230067641A (enExample) |
| CN (2) | CN115531352B (enExample) |
| AU (1) | AU2021340733A1 (enExample) |
| BR (1) | BR112023004677A2 (enExample) |
| CA (1) | CA3191463A1 (enExample) |
| DK (1) | DK4210682T3 (enExample) |
| FI (1) | FI4210682T3 (enExample) |
| HR (1) | HRP20260727T1 (enExample) |
| IL (1) | IL301227A (enExample) |
| LT (1) | LT4210682T (enExample) |
| MX (1) | MX2023002902A (enExample) |
| PT (1) | PT4210682T (enExample) |
| RS (1) | RS68167B1 (enExample) |
| SI (1) | SI4210682T1 (enExample) |
| SM (1) | SMT202600235T1 (enExample) |
| WO (1) | WO2022056392A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018067882A1 (en) | 2016-10-05 | 2018-04-12 | Titan Pharmaceuticals, Inc. | Implantable devices for drug delivery with reduced burst release |
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| SI4210682T1 (sl) * | 2020-09-14 | 2026-07-31 | EyePoint, Inc. | Bioerozibilni očesni vložek za dovajanje zdravil in terapevtska metoda |
| WO2022251710A2 (en) | 2021-05-28 | 2022-12-01 | Sight Sciences, Inc. | Intraocular devices, systems, and methods |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| IL315331A (en) * | 2022-03-11 | 2024-10-01 | Eyepoint Pharmaceuticals Inc | A method of preventing age-related ocular degeneration by providing a drug entry mechanism into the eye |
| US20250186398A1 (en) * | 2022-03-11 | 2025-06-12 | EyePoint Pharmaceuticals, Inc. | Continuous dosing regimen for treatment of a condition of the eye |
| TW202345804A (zh) * | 2022-03-11 | 2023-12-01 | 美商視點製藥有限公司 | 治療濕性老年黃斑部病變(Wet Age-related Macular Degeneration)之方法 |
| US20240024093A1 (en) | 2022-07-22 | 2024-01-25 | SpyGlass Pharma, Inc. | Intraocular drug delivery systems and methods of use |
| JP2025525881A (ja) * | 2022-08-16 | 2025-08-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 眼内使用するためのニンテダニブの医薬製剤 |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| CN121568687A (zh) | 2023-04-27 | 2026-02-24 | 艾博莱特克斯有限公司 | 包含聚乙烯醇的弹性体基质 |
| KR102618788B1 (ko) * | 2023-06-19 | 2023-12-28 | 국민대학교산학협력단 | 알티라티닙 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 안질환 예방 또는 치료용 약학 조성물 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| US6713081B2 (en) * | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
| US8871241B2 (en) | 2002-05-07 | 2014-10-28 | Psivida Us, Inc. | Injectable sustained release delivery devices |
| DK1592407T3 (da) * | 2003-01-24 | 2010-04-19 | Psivida Inc | Indretning med depotvirkning og fremgangsmåde til okulær indgivelse af carbonanhydraseinhibitorer |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| WO2008033562A2 (en) | 2006-09-15 | 2008-03-20 | Xcovery, Inc. | Kinase inhibitor compounds |
| CN101679356A (zh) | 2007-04-05 | 2010-03-24 | 辉瑞产品公司 | 适用于治疗哺乳动物异常细胞生长的6-[2-（甲基-氨甲酰基）苯基硫基]-3-e-[2-(吡啶-2-基)乙烯基]吲唑的晶型 |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US20110238036A1 (en) | 2009-12-23 | 2011-09-29 | Psivida Us, Inc. | Sustained release delivery devices |
| CA2848397C (en) * | 2011-09-14 | 2022-04-26 | Forsight Vision5, Inc. | Ocular insert apparatus and methods |
| WO2013071264A1 (en) | 2011-11-11 | 2013-05-16 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
| US20160317438A1 (en) | 2015-04-29 | 2016-11-03 | Psivida Us, Inc. | Injectable sustained release intraocular device |
| AU2016361579B2 (en) | 2015-11-25 | 2022-08-04 | Incept, Llc | Shape changing drug delivery devices and methods |
| PT109154B (pt) * | 2016-02-12 | 2019-11-05 | Univ De Coimbra | Tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos |
| SG11201901962QA (en) | 2016-09-29 | 2019-04-29 | Equinox Sciences Llc | Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof |
| EP3570888A1 (en) * | 2017-03-03 | 2019-11-27 | MacRegen, Inc. | Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents |
| CA3066437A1 (en) * | 2017-06-13 | 2018-12-20 | EyePoint Pharmaceuticals, Inc. | Bioerodible drug delivery devices |
| CN112165923B (zh) * | 2018-04-19 | 2023-07-21 | 埃弗拉兹疗法有限公司 | 用于将物质注射到身体组织或器官的夹层中的装置 |
| WO2020177678A1 (zh) * | 2019-03-04 | 2020-09-10 | 江苏恒瑞医药股份有限公司 | 多靶点酪氨酸激酶抑制剂与egfr抑制剂联合在制备治疗肿瘤的药物中的用途 |
| SI4210682T1 (sl) * | 2020-09-14 | 2026-07-31 | EyePoint, Inc. | Bioerozibilni očesni vložek za dovajanje zdravil in terapevtska metoda |
| US20250186398A1 (en) * | 2022-03-11 | 2025-06-12 | EyePoint Pharmaceuticals, Inc. | Continuous dosing regimen for treatment of a condition of the eye |
-
2021
- 2021-09-13 SI SI202130442T patent/SI4210682T1/sl unknown
- 2021-09-13 PT PT218677656T patent/PT4210682T/pt unknown
- 2021-09-13 EP EP25211173.7A patent/EP4696325A3/en active Pending
- 2021-09-13 CN CN202211200614.5A patent/CN115531352B/zh active Active
- 2021-09-13 RS RS20260673A patent/RS68167B1/sr unknown
- 2021-09-13 HR HRP20260727TT patent/HRP20260727T1/hr unknown
- 2021-09-13 FI FIEP21867765.6T patent/FI4210682T3/fi active
- 2021-09-13 CA CA3191463A patent/CA3191463A1/en active Pending
- 2021-09-13 WO PCT/US2021/050085 patent/WO2022056392A1/en not_active Ceased
- 2021-09-13 LT LTEPPCT/US2021/050085T patent/LT4210682T/lt unknown
- 2021-09-13 IL IL301227A patent/IL301227A/en unknown
- 2021-09-13 DK DK21867765.6T patent/DK4210682T3/da active
- 2021-09-13 EP EP21867765.6A patent/EP4210682B1/en active Active
- 2021-09-13 CN CN202180019407.7A patent/CN115243682A/zh active Pending
- 2021-09-13 AU AU2021340733A patent/AU2021340733A1/en active Pending
- 2021-09-13 BR BR112023004677A patent/BR112023004677A2/pt unknown
- 2021-09-13 JP JP2023515802A patent/JP7848190B2/ja active Active
- 2021-09-13 MX MX2023002902A patent/MX2023002902A/es unknown
- 2021-09-13 SM SM20260235T patent/SMT202600235T1/it unknown
- 2021-09-13 KR KR1020237012132A patent/KR20230067641A/ko active Pending
-
2022
- 2022-02-14 US US17/671,060 patent/US12551368B2/en active Active
-
2026
- 2026-01-23 US US19/458,141 patent/US20260151260A1/en active Pending
- 2026-01-23 US US19/458,091 patent/US20260191682A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115243682A (zh) | 2022-10-25 |
| DK4210682T3 (da) | 2026-06-08 |
| US20260151260A1 (en) | 2026-06-04 |
| EP4210682B1 (en) | 2026-03-25 |
| PT4210682T (pt) | 2026-05-27 |
| FI4210682T3 (fi) | 2026-05-28 |
| HRP20260727T1 (hr) | 2026-07-31 |
| AU2021340733A1 (en) | 2023-05-18 |
| JP2023541056A (ja) | 2023-09-27 |
| US20260191682A1 (en) | 2026-07-09 |
| CN115531352A (zh) | 2022-12-30 |
| EP4696325A3 (en) | 2026-05-06 |
| MX2023002902A (es) | 2023-04-05 |
| CN115531352B (zh) | 2025-04-25 |
| KR20230067641A (ko) | 2023-05-16 |
| JP7848190B2 (ja) | 2026-04-20 |
| US20220168142A1 (en) | 2022-06-02 |
| WO2022056392A1 (en) | 2022-03-17 |
| EP4696325A2 (en) | 2026-02-18 |
| SMT202600235T1 (it) | 2026-07-16 |
| IL301227A (en) | 2023-05-01 |
| SI4210682T1 (sl) | 2026-07-31 |
| AU2021340733A9 (en) | 2024-04-18 |
| BR112023004677A2 (pt) | 2023-05-09 |
| CA3191463A1 (en) | 2022-03-17 |
| US12551368B2 (en) | 2026-02-17 |
| LT4210682T (lt) | 2026-06-10 |
| EP4210682A1 (en) | 2023-07-19 |
| EP4210682A4 (en) | 2024-10-16 |